Niaz

Eskayef Pharmaceuticals Ltd.

Eskayef Pharmaceuticals Ltd. is one of the leaders in Bangladesh's pharmaceutical industry. With its presence across the world, it has earned coveted accreditations from the US FDA, UK MHRA, EU EMA, TGA Australia and more. Eskayef spread its wings in 1990 when the Bangladesh operations of SmithKline & French, USA was acquired by Transcom Group. Eskayef prides itself on being a trusted manufacturer of top-quality medicine for Bangladesh and the world. History: 1979: The history of Eskayef traces back to 1979, when the company was incorporated in Bangladesh as a subsidiary of the world renowned multinational pharmaceutical company SmithKline & French (SK&F), USA. 1990: SmithKline & French's Bangladesh operation was acquired by Transcom Group in the wake of the merger between SmithKline & French, USA and Beecham, UK. That was the first instance of taking over of any multinational company by a Bangladeshi entity. After the acquisition, the new company was named Eskayef Bangladesh Limited. 1999: • Pioneering of Pellet Technology in Bangladesh. 2001: • Beginning of Animal Health Business 2003-2004: • Beginning of International Business 2008: • Accreditation by UK MHRA & EU GMP • Commissioning of Dedicated Cephalosporin Plant 2009-2010: • Accreditation by TGA Australia 2011-2012: • Accreditation by VMD UK • Starts manufacturing Insulin for Novo Nordisk 2013: • Commissioning of Sterile Unit at Tongi 2014-2015: • Approval by UNICEF • Reaccreditation by UK MHRA 2016: Commissioning of Rupgonj Plant 2017: • As Eskayef continued to increase its presence in the international arena, it was the time to project Eskayef as a figure not only in Bangladesh but also in the global pharmaceutical world. This led to the company emerging as Eskayef Pharmaceuticals Limited. • Commissioning of future-ready and state-of the art manufacturing plant, Faraaz Ayaaz Hossain Building and its accreditation by UK MHRA. 2018: With the mission of fighting together and winning the battle against Cancer, Eskayef establishes dedicated Oncology plant with 1st time in Bangladesh ISOLATOR technology. 2020: • Eskayef redefines its capability by introducing Remivir injection, the 1st generic Remdesivir brand in the world for treating hospitalized Covid-19 patients • Eskayef Oncology manufacturing plant receives EU GMP Approval, which is the 1st and only EU GMP certified Oncology Facility in Bangladesh and one of very few in Asia 2021: • Eskayef introduces Monuvir brand, the 1st Generic Molnupiravir brand in the world for the treatment of COVID-19 patients • Eskayef introduces Paxovir brand, the 1st Generic Nirmatrelvir + Ritonavir brand in the world for the treatment of COVID-19 patients • Eskayef Oncology manufacturing plant receives ANVISA Brazil Approval, which is the 1st and only ANVISA Brazil certified Oncology Facility in Bangladesh 2022: • The Faraaz Ayaaz Hossain Building manufacturing facility receives the prestigious US FDA approval for Oral Solid dosage forms in March 2022 • Creating a remarkable history, Eskayef achieves the US FDA approval for Injectable Manufacturing Facility in September 2022, which is the 1st & only US FDA accredited injectable manufacturing facility in Bangladesh pharmaceutical industry Global Footprint: Eskayef exports to 67 countries across 6 continents Multinational Partners: Eskayef Pharmaceuticals Limited is recognized as a model of trust and efficiency by clue-chip multinationals. Technology Transfer: • Manufacturing insulin for world famous Novo Nordisk, from the state-of-the-art & dedicated insulin manufacturing facility since 2012. • In January 2018, Eskayef signed an historic agreement with Novo Nordisk to become its first-ever partner to contract manufacture its cutting-edge modern Penfill insulin. Manufacturing Under License: Eskayef is manufacturing products for Servier, France since 2009 Business Alliance: Marketing and selling world famous eye care products from Allergan USA and Ireland.